Henry Schein Inc at JPMorgan Healthcare Conference Transcript

Jan 11, 2023 / 05:00PM GMT
Rachel Marie Vatnsdal Olson - JPMorgan Chase & Co, Research Division - Analyst

Hi, everyone. This is Rachel Vatnsdal from the life science tools and diagnostics team. I'm joined by Stanley Bergman and Ronald South, CEO and CFO of Henry Schein. So today, this session is going to be 40 minutes. It's really going to be more of a fireside chat style. So it's going to be Q&A the entire time. For those of you listening online via the webcast, feel free to submit a question via the Q&A function. And then for those of you that are in person, feel free to raise your hand. We have mic runners throughout the room, so they will hand you a mic to ask a question.

Questions and Answers:

Rachel Marie Vatnsdal Olson - JPMorgan Chase & Co, Research Division - Analyst

So for that, Stanley, if you could just kind of walk us through the story for those of us new to this, I spent a few minutes talking about the business. How 2022 has gone so far, and how Henry Schein has come out of the Pandemic a stronger company?

Stanley M. Bergman -
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot